Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025.

IF 25.4 1区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

MMWR. Morbidity and mortality weekly report Pub Date : 2025-02-27 DOI:10.15585/mmwr.mm7406a1

Ruth Link-Gelles, Sean Chickery, Alexander Webber, Toan C Ong, Elizabeth A K Rowley, Malini B DeSilva, Kristin Dascomb, Stephanie A Irving, Nicola P Klein, Shaun J Grannis, Michelle A Barron, Sarah E Reese, Charlene McEvoy, Tamara Sheffield, Allison L Naleway, Ousseny Zerbo, Colin Rogerson, Wesley H Self, Yuwei Zhu, Adam S Lauring, Emily T Martin, Ithan D Peltan, Adit A Ginde, Nicholas M Mohr, Kevin W Gibbs, David N Hager, Matthew E Prekker, Amira Mohamed, Nicholas Johnson, Jay S Steingrub, Akram Khan, Jamie R Felzer, Abhijit Duggal, Jennifer G Wilson, Nida Qadir, Christopher Mallow, Jennie H Kwon, Cristie Columbus, Ivana A Vaughn, Basmah Safdar, Jarrod M Mosier, Estelle S Harris, James D Chappell, Natasha Halasa, Cassandra Johnson, Karthik Natarajan, Nathaniel M Lewis, Sascha Ellington, Emily L Reeves, Jennifer DeCuir, Meredith McMorrow, Clinton R Paden, Amanda B Payne, Fatimah S Dawood, Diya Surie

{"title":"Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025.","authors":"Ruth Link-Gelles, Sean Chickery, Alexander Webber, Toan C Ong, Elizabeth A K Rowley, Malini B DeSilva, Kristin Dascomb, Stephanie A Irving, Nicola P Klein, Shaun J Grannis, Michelle A Barron, Sarah E Reese, Charlene McEvoy, Tamara Sheffield, Allison L Naleway, Ousseny Zerbo, Colin Rogerson, Wesley H Self, Yuwei Zhu, Adam S Lauring, Emily T Martin, Ithan D Peltan, Adit A Ginde, Nicholas M Mohr, Kevin W Gibbs, David N Hager, Matthew E Prekker, Amira Mohamed, Nicholas Johnson, Jay S Steingrub, Akram Khan, Jamie R Felzer, Abhijit Duggal, Jennifer G Wilson, Nida Qadir, Christopher Mallow, Jennie H Kwon, Cristie Columbus, Ivana A Vaughn, Basmah Safdar, Jarrod M Mosier, Estelle S Harris, James D Chappell, Natasha Halasa, Cassandra Johnson, Karthik Natarajan, Nathaniel M Lewis, Sascha Ellington, Emily L Reeves, Jennifer DeCuir, Meredith McMorrow, Clinton R Paden, Amanda B Payne, Fatimah S Dawood, Diya Surie","doi":"10.15585/mmwr.mm7406a1","DOIUrl":null,"url":null,"abstract":"<p><p>COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.</p>","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"74 6","pages":"73-82"},"PeriodicalIF":25.4000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867580/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MMWR. Morbidity and mortality weekly report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7406a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.

查看原文本刊更多论文

2024-2025年COVID-19疫苗在18岁以上成年人中的有效性中期评估——VISION和IVY网络，2024年9月-2025年1月

在2023-24呼吸道季节期间，COVID-19疫苗避免了约6.8万人住院。2024年6月，CDC和免疫实践咨询委员会（ACIP）建议所有年龄≥6个月的人接种2024-2025年COVID-19疫苗，该疫苗针对欧米克隆jn1和jn1衍生亚谱系。在一个cdc资助的疫苗有效性（VE）网络中，对2024-2025年COVID-19疫苗在2024年9月至2025年1月期间在一个≥18岁的成年人中与COVID-19相关的急诊科（ED）或急诊（UC）就诊的中期有效性进行了评估，在两个网络中对免疫功能正常的≥65岁成年人中与COVID-19相关的住院进行了评估，在一个网络中对免疫功能低下的≥65岁成年人中与COVID-19相关的住院进行了评估。在年龄≥18岁的成年人中，在接种疫苗后的头7-119天内，与covid -19相关的ED/UC就诊的VE为33% （95% CI = 28%-38%）。在来自两个CDC网络的年龄≥65岁的免疫能力成年人中，在接种疫苗后的头7-119天内，与covid -19相关的住院率的VE估计为45% （95% CI = 36%-53%）和46% （95% CI = 26%-60%）。在一个网络中年龄≥65岁且免疫功能低下的成年人中，在接种疫苗后的前7-119天，VE为40% （95% CI = 21%-54%）。这些研究结果表明，与未接种2024-2025剂量相比，接种2024-2025剂量的COVID-19疫苗可提供额外的保护，防止与COVID-19相关的ED/UC遭遇和住院，并支持当前CDC和ACIP的建议，即所有年龄≥6个月的人接种2024-2025剂量的COVID-19疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

MMWR. Morbidity and mortality weekly report PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -

CiteScore

65.40

自引率

0.90%

发文量

309

期刊介绍： The Morbidity and Mortality Weekly Report (MMWR ) series is prepared by the Centers for Disease Control and Prevention (CDC). Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.